Compare VALN & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALN | ETON |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 820.0M | 498.8M |
| IPO Year | 2021 | 2018 |
| Metric | VALN | ETON |
|---|---|---|
| Price | $8.71 | $16.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $15.75 | ★ $29.67 |
| AVG Volume (30 Days) | 19.7K | ★ 270.8K |
| Earning Date | 11-20-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $211,089,992.00 | $70,316,000.00 |
| Revenue This Year | $5.08 | $113.27 |
| Revenue Next Year | $12.53 | $36.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.48 | ★ 102.77 |
| 52 Week Low | $3.62 | $11.09 |
| 52 Week High | $12.25 | $23.00 |
| Indicator | VALN | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 49.52 |
| Support Level | $8.62 | $16.13 |
| Resistance Level | $9.10 | $17.05 |
| Average True Range (ATR) | 0.29 | 0.76 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 12.25 | 79.06 |
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.